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Introduction: Cardio-renal syndromes are characterized by the impairment of cardiac and renal functions. Plasma
and urinary neutrophil gelatinase-associated lipocalin (NGAL), and plasma B-type natriuretic peptide (BNP) are
markers of acute kidney injury (AKI) and heart failure (HF), respectively.
The aim of this study was to assess the effect of the reduction of glomerular filtration rate (GFR) on plasma BNP and on
plasma and urinary NGAL concentrations in stable chronic kidney disease (CKD) patients at different functional stages.
Methods: GFR (99mTc-DTPA), plasma BNP, and plasma and urinary concentrations of NGAL were measured in 310
clinically stable CKD patients, at functional stages from 1 to 5. Serum and urinary low-molecular-weight proteins
cystatin C and β2-microglobulin, and urinary tubular enzymes were measured for comparison. Plasma BNP, NGAL,
cystatin C and β2-microglobulin were measured also in 31 maintenance hemodialysis patients.
Results: Plasma NGAL increased with the reduction of GFR in CKD patients from stage 2. In the different CKD stages
modest differences were found for BNP values. Urinary NGAL increased slightly but significantly in patients at CKD
stages 4 and 5, similarly to urinary cystatin C and β2-microglobulin. In maintenance hemodialysis patients, plasma NGAL
and BNP were markedly increased, and high-flux hemodialysis significantly decreased their plasma concentrations.
Conclusions: Plasma NGAL increases markedly with the reduction in GFR, generating a very high number of false
positive diagnoses of AKI in stable CKD patients. The grade of GFR impairment and the cause of kidney disease have a
lower effect on urinary NGAL and on plasma BNP. In any case, specific reference values of NGAL and BNP should be
used in chronic kidney disease patients, according to their functional stage, when assessing acute kidney injury, heart
failure, and cardio-renal syndromes in patients with impaired GFR.Introduction
Acute or chronic impairment of both cardiac and renal
functions characterize cardio-renal syndromes [1]. Neu-
trophil gelatinase-associated lipocalin (NGAL), either in
plasma or urine, is a marker of acute kidney injury (AKI),
while increased plasma levels of B-type natriuretic peptideCorrespondence: carlo.donadio@med.unipi.it
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reproduction in any medium, provided the or(BNP) suggest heart failure. Renal impairment in heart
failure patients is characterized by decreased glomerular
filtration rate (GFR) and increased urinary excretion of
albumin and NGAL [2]. Plasma NGAL, which correlates
with AKI severity [3], is also a strong predictor of adverse
outcomes in acute heart failure patients [4]. These data
suggest that renal damage has a role in determining the
prognosis of acute heart failure patients [5]. In patients
with heart failure and chronic kidney disease (CKD),. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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renal function [6]. Plasma BNP also increases, independ-
ently from heart failure, in CKD patients with impaired
GFR, due to reduction of its renal clearance [7,8]. Only
few data are available on the reference ranges of plasma
and urinary NGAL in normal subjects [9]. In any case,
whether the accuracy of plasma and urinary NGAL as
indicators of AKI is affected by the impairment of GFR
remains undefined [10]. This information is particularly
relevant due to the increase of AKI in CKD patients;
that is, acute-on-chronic kidney injury.
The aim of this study was to assess the effect of the
reduction of GFR on plasma BNP and plasma and urinary
NGAL and, for comparison, on serum and urinary con-
centrations of low-molecular-weight proteins (LMWPs)
and urinary activity of tubular enzymes in stable CKD pa-
tients at different functional stages.
Materials and methods
Patient recruitment and selection
CKD patients were referred to the laboratory of the
Nephrology Division of the Department of Internal
Medicine of Pisa University for the assessment of GFR,
from January 2007 to June 2009. The majority of patients
(≈65%) came from outpatient clinics, the remainder were
in-hospital patients. CKD had been diagnosed according
to National Kidney Foundation K-DOQI guidelines [11].
Inclusion criterion were age >18 years and diagnosis of
clinically stable CKD at any stage. Potential living kidney
donors, post-donation kidney donors and renal transplant
recipients were also referred for the measurement of GFR.
In donors, measurements were performed between 3 and
6 months post nephrectomy. Exclusion criteria were AKI,
primary tubular diseases, and recent administration of
potentially nephrotoxic drugs. AKI was excluded on the
basis of clinical history, reported constancy of urinary
output and of serum creatinine levels the week before
GFR measurement.
The study was approved by the Institutional Ethical
Committee of Azienda Ospedaliero-Universitaria Pisana
and conducted in accordance with guidelines of Helsinki
declaration and with the Principles of the Declaration of
Istanbul as outlined in the Declaration of Istanbul on
Organ Trafficking and Transplant Tourism. All patients
gave their informed consent.
Study protocol
GFR, serum creatinine, plasma BNP, plasma and urinary
NGAL, plasma and urinary concentrations of LMWPs
cystatin C and β2-microglobulin, urinary albumin excretion
and urinary activities of tubular enzymes gamma-glutamyl
transferase (GGT), lactate dehydrogenase (LDH), and
N-acetyl-β-D-glucosaminidase (NAG) were measured in
the 310 CKD patients at the time of GFR measurement.Plasma BNP and NGAL, and serum creatinine, cystatin
C and β2-microglobulin were measured in maintenance
hemodialysis (MHD) patients before and at the end of a
mid-week hemodialysis session. Serum and urinary samples
were divided into Eppendorf tubes and stored at −20°C.
Measurement of glomerular filtration rate (reference test)
GFR was measured as the renal clearance of 99mTc-DTPA
[12,13], and was scaled to the standard body surface of
1.73 m2. Patients were assigned to CKD stages on the
basis of the value of the measured GFR: CKD stage 1,
GFR >90 ml/minute/1.73 m2; CKD stage 2, GFR 60 to
90 ml/minute/1.73 m2; CKD stage 3a, GFR 45 to
60 ml/minute/1.73 m2; CKD stage 3b, GFR 30 to
45 ml/minute/1.73 m2; CKD stage 4, GFR 15 to 30 ml/
minute/1.73 m2; CKD stage 5, GFR <15 ml/minute/
1.73 m2 [11].
Measurement of blood and urinary concentrations of NGAL,
creatinine, cystatin C and β2-microglobulin, of plasma BNP,
and of urinary excretion of albumin and tubular enzymes
(index tests)
The Alere Triage® System (Alere San Diego, Inc., San Diego,
CA, USA ) was used to determine plasma NGAL (Alere
Triage® NGAL Test). The measurement utilizes antibodies
with low affinity to the dimeric forms of NGAL. The upper
limit of the reference range is 153 ng/ml (90% confidence
interval, 142 to 182 ng/ml) (Triage® NGAL Product Insert).
To measure urine NGAL, an antibody sandwich im-
munoassay was utilized for urine samples. Test samples
were added to a 384-well plate, containing a calibration
curve and control samples. The plates were read by a
fluorometer. The upper limits of the reference ranges
reported for urine NGAL are 131.7 ng/ml (Urine NGAL
Abbott, Product Insert; Abbott Ireland, Longford, Ireland),
and 107 μg/l (males, 91 μg/l; females, 129 μg/l) [14].
Fractional excretion (FE) of NGAL was calculated as:
FE ¼ 100 urinary NGAL serum creatinineð Þ
= plasma NGAL urinary creatinineð Þ
Plasma BNP was measured with the Alere Triage®
System, utilizing antibodies against BNP (Alere Triage®
BNP Test). The upper limit of the reference range is
100 pg/ml.
The average coefficients of variation for plasma NGAL
and BNP, measured by means of the Alere Triage® System
from two replicates of plasma specimens at four analyte
levels tested at two separate times daily for 20 days,
ranged between 9.2 and 12.8% for BNP and between 12.5
and 16.0% for NGAL (Triage® CardioRenal Panel Product
Insert, 2011).
Creatinine was measured with a rate-blanked creatinine/
Jaffé method (CREA Roche/Hitachi for Hitachi 917; Roche
Figure 1 Flow diagram of the chronic kidney disease patients
that entered the study.
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for serum concentration were 0.50 to 0.90 mg/dl in females
and 0.70 to 1.20 mg/dl in males.
Cystatin C was measured with a particle-enhanced
immune-nephelometric method (N Latex Cystatin C; Dade
Behring, Marburg, Germany). The reference intervals
for serum concentrations were 0.53 to 0.95 mg/l, without
differences between males and females.
β2-Microglobulin was measured with an immune-
enzymic method (AxSym β2-Microglobulin; Abbott,
Wiesbaden, Germany). The mean reference value for serum
concentration was 0.99 ± 0.16, without differences between
males and females.
Urinary albumin was measured with an immune-nephe-
lometric method (N antiserum to human albumin; Dade
Behring, Marburg, Germany).
For measurement of urinary excretion of tubular en-
zymes, urinary activities of brush border enzyme GGT
and cytosolic enzyme LDH were measured with methods
routinely used for the determinations of these enzymes in
plasma (Boehringer Mannheim for Hitachi 911; Boehringer
Mannheim Biochemia, Basel, CH). Urinary activities of
lysosomal enzyme NAG were measured by automating
for Hitachi 911, a manual method (Boehringer Mannheim
Biochemia).
FE of LMWPs was calculated with a formula similar to
that for FE of NGAL. Since urinary NGAL is commonly
expressed as μg/l, all other proteins and enzymes were
expressed also as mg/l, mg/dl or u/l. The relative relation-
ships are not affected if all data are normalized for urinary
creatinine excretion.
Statistical analysis
The reference intervals of all examined index tests have
been calculated using a nonparametric method, as recom-
mended by the Clinical and Laboratory Standards Institute
[15]. These reference intervals take the central 95% of our
reference population; that is, the 33 potential kidney donors
(eight males, 25 females; age 25 to 66, mean 50.2 years).
Note the high prevalence of women among kidney donors,
and the difference in age distribution in comparison with
the examined patients.
The correlation coefficients between GFR and the index
tests were measured after logarithmic transformation of
data. The significance of the differences among correlation
coefficients was tested [16]. The significance of the dif-
ferences between two independent samples and between
two paired samples was tested using the nonparametric
Mann–Whitney and Wilcoxon tests, respectively. The
diagnostic accuracy of markers was assessed using receiver-
operating characteristic analysis. Statistical analysis was
performed using MedCalc (version 12.4.0.0; MedCalc
Software, Mariakerke, Belgium). P < 0.05 was considered
significant.Results
The flow diagram of the 375 eligible patients, according
to the STARD initiative [17], is reported in Figure 1.
Fifty-four patients had inadequate collection of blood or
urine samples for the determination of index tests. The
measurement of GFR (reference test) was inadequate in
11 patients. The data for the remaining 310 CKD patients
and 31 MHD patients are analyzed in the present study.
Their main anthropometric and clinical data are presented
in Table 1.
The dialysis vintage of the 31 MHD patients ranged
between 0.2 and 17 years (mean 3.5 ± 4.2 years). All pa-
tients were treated with a schedule of three sessions/
week, mean length 4.0 ± 0.2 hours. Mean blood flow was
312 ± 42 ml/minute, and dialysate flow was fixed at 700 ml/
minute. Twenty-three hemodialysis treatments were per-
formed using a low-flux membrane (polysulfone), and
21 treatments were performed with high-flux membranes
(cellulose triacetate or acrylonitrile or sodium methallyl
sulfonate copolymer).
Reference ranges
The reference intervals determined in the potential kidney
donors were: plasma NGAL, 20 to 133 ng/ml; plasma BNP,
5 to 47 pg/ml; serum creatinine, 0.6 to 1.3 mg/dl; serum
cystatin C, 0.4 to 1.06 mg/l; serum β2-microglobulin, 0.7 to
1.8 mg/l; urinary NGAL, 0 to 33 ng/ml; urinary albumin,
0.1 to 9.3 mg/dl; urinary cystatin C, 0 to 0.4 mg/l; urinary
β2-microglobulin, 0.1 to 0.29 mg/l; GGT, 5 to 183 u/l;
LDH, 0.1 to 86 u/l; and NAG, 1 to 16 u/l.
Table 1 Demographic and clinical data for chronic kidney disease patients and maintenance hemodialysis patients
Chronic kidney disease patients Maintenance hemodialysis patients
Range Mean ± SD Range Mean ± SD
Age (years) 17 to 82 50.5 ± 14.2 36 to 92 69.9 ± 15.1
Body weight (kg) 34 to 119.4 73.4 ± 15.2 33 to 122 68.6 ± 18.9
Height (cm) 139 to 191 166 ± 9.4 148 to 182 167 ± 9.9
Body mass index (kg/m2) 13 to 42.8 26.5 ± 4.7 15 to 39 24.2 ± 5.8
Serum creatinine (mg/dl) 0.5 to 7.5 1.7 ± 1.2 2.4 to 17.0 8.6 ± 3.2
Native kidney disease (n)
Chronic nephropathies 63 2
Chronic glomerulonephritis 50 7
Renal transplant recipient 42
Diabetic nephropathy 36 6
Ischemic nephropathy 15 10
Oncological diseases 12
Interstitial nephritis 8 3
APKD 6 3
Potential kidney donor 33
Living kidney donor 45
Chronic kidney disease patients: 161 males, 149 females; maintenance hemodialysis patients: 23 males, eight females. APKD, autosomal dominant polycystic kidney disease;
SD, standard deviation.
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Effect of glomerular filtration rate impairment on NGAL
and BNP
Plasma NGAL increased with the reduction of GFR
(Table 2). A significant increase in mean values wasTable 2 Plasma and urinary concentrations of NGAL and BNP
various markers of GFR impairment and urinary excretion of
CKD stage 1 CKD stage 2 CKD sta
Number 48 85 64
Age (years) 44.3 ± 2.1 49.1 ± 1.4 49.2 ±
GFR (ml/minute/1.73 m2) 111.3 ± 2.5 72.4 ± 1.0**** 52.9 ± 0.
Plasma NGAL (ng/ml) 66 ± 6.4 114 ± 10*** 186 ± 18
Plasma BNP (pg/ml) 20 ± 4.3 24 ± 3.4 40 ± 7
Serum creatinine (mg/dl) 0.8 ± 0.03 1.1 ± 0.03**** 1.4 ± 0.1
Serum cystatin C (mg/l) 0.8 ± 0.03 1.1 ± 0.03**** 1.3 ± 0.0
Serum β2-microglobulin (mg/l) 1.3 ± 0.06 1.8 ± 0.06**** 2.3 ± 0.1
Urinary NGAL (ng/ml) 13 ± 3 11 ± 2 15 ±
Urinary albumin (mg/dl) 16 ± 8.4 39 ± 18.9 38 ± 1
Urinary cystatin C (mg/l) 0.1 ± 0.02 0.1 ± 0.03 0.2 ± 0
Urinary β2-microglobulin (mg/l) 0.3 ± 0.13 0.3 ± 0.12 0.8 ± 0
Urinary GGT (u/l) 71 ± 7.0 49 ± 4.3** 36 ± 3.9
Urinary LDH (u/l) 31 ± 3.7 32 ± 4.2 25 ± 6
Urinary NAG (u/l) 6.1 ± 0.5 6.3 ± 0.5 5.4 ±
Mean values ± standard errors of the mean are reported. The significance of the differe
*P < 0.05; **P < 0.01; ***P < 0.001; ***P < 0.0001. In MHD patients, plasma NGAL, BNP, se
before the beginning of the dialysis session. BNP, B-type natriuretic peptide; CKD, chro
rate; LDH, lactate dehydrogenase; NAG, N-acetyl-β-D-glucosaminidase; MHD, maintenaalready found at CKD stage 2. Plasma NGAL then pro-
gressively increased with the reduction of GFR and was
even higher in MHD patients, up to 16 times the values at
CKD stage 1. The mean values of serum creatinine, cysta-
tin C, and β2-microglobulin also progressively increasedin comparison with serum and urinary concentrations of
tubular enzymes
ge 3a CKD stage 3b CKD stage 4 CKD stage 5 MHD
50 43 20 31
1.7 52.1 ± 2.3* 58.3 ± 2.2**** 54.6 ± 2.4** 69.9 ± 2.8****
5**** 38.1 ± 0.6**** 21.6 ± 0.6**** 11.0 ± 0.6****
**** 273 ± 26**** 559 ± 59**** 862 ± 95**** 1093 ± 56****
.2* 32 ± 5.4 62.9 ± 13** 86 ± 45 1116 ± 248
5**** 1.8 ± 0.17**** 3.0 ± 0.16**** 5.1 ± 0.28**** 8.6 ± 0.6****
4**** 1.7 ± 0.06**** 2.5 ± 0.11**** 3.9 ± 0.26**** 5.2 ± 0.2****
0**** 3.3 ± 0.18**** 5.8 ± 0.33**** 9.5 ± 0.71**** 32.3 ± 1.6****
4 21 ± 6 38 ± 10* 90 ± 24**
1.3 85 ± 31.9* 69 ± 11.4*** 136 ± 64.5
.08 0.2 ± 0.08 0.4 ± 0.10** 2.9 ± 1.15
.26* 1.7 ± 0.66** 4.7 ± 1.14*** 19 ± 4.6**
*** 46 ± 5.9** 44 ± 9.1* 35 ± 7.8***
.0 28 ± 4.3 24 ± 3.6 67 ± 32.6
0.4 6.2 ± 0.5 7.3 ± 0.9 5.6 ± 0.7
nces with the mean values of the group of patients at CKD stage 1 is indicated:
rum creatinine, cystatin C and β2-microglobulin were measured immediately
nic kidney disease; GGT, gamma-glutamyl-transferase; GFR, glomerular filtration
nce hemodialysis patients; NGAL, neutrophil gelatinase-associated lipocalin.
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found for BNP in the different CKD stages, while BNP
was markedly increased in MHD patients. Urinary NGAL
was significantly increased only in patients at CKD stages
4 and 5. A significant increase in mean values of urinary
cystatin C was found starting from CKD stage 4, while
urinary β2-microglobulin was significantly higher already
at CKD stage 3a. Urinary excretion of LDH and NAG
were similar at all stages of CKD, while values of GGT
decreased slightly but significantly with the impairment
of GFR, starting from CKD stage 2.
The data for individual patients (Figure 2) indicate
that plasma NGAL markedly and progressively increased,
like serum creatinine, cystatin C and β2-microglobulin,
with the reduction of GFR (Table 2). The correlation be-
tween plasma NGAL and these markers was highly signifi-
cant (R = 0.745 with creatinine; R = 0.731 with cystatin C;
R = 0.773 with β2-microglobulin). However, the correl-
ation of plasma NGAL with GFR was significantly lower
(P < 0.0001) than that of serum creatinine, cystatin C and
β2-microglobulin. Plasma BNP increased slightly with the
reduction of GFR (Figure 2) and its correlation with GFR
was quite weak. Urinary NGAL significantly increased
with the reduction of GFR, with a behavior similar to
urinary cystatin C and β2-microglobulin (Figure 2, Table 2).
Albuminuria had a weak but statistically significant correl-
ation (r = 0.338, P < 0.001) with urinary NGAL.
The accuracy of plasma NGAL as an indicator of GFR
impairment was significantly lower than that of serum
creatinine, cystatin C and β2-microglobulin. The accuracy
of urine NGAL and plasma BNP as indicators of GFR im-
pairment was quite modest (Table 3).
The mathematic function that expresses the relationship
between the ideal marker and GFR is an equilateral hyper-
bole. The curve of the ideal marker was generated assum-
ing arbitrarily as 1 its plasma level at the value of GFR
measured in CKD patients at stage 1 (111.3 ml/minute/
1.73 m2). The relationships of various serum markers
with GFR were different (Figure 3). In fact, while plasma
β2-microglobulin, creatinine and cystatin C increased lessFigure 2 Correlations with glomerular filtration rate of plasma and ur
natriuretic peptide. Regression lines, regression equations, coefficients of d
reported. BNP, B-type natriuretic peptide; GFR, glomerular filtration rate; NGAthan expected relative to GFR, plasma NGAL increased
more than expected. Furthermore, the correlation among
the various serum markers was different in the different
CKD stages (Table 2, Figure 3). In particular, in CKD stage
2 the increases of serum creatinine, cystatin C and β2-
microglobulin were identical (1.4 times the values measured
in patients at CKD stage 1). Starting from CKD stage
3a the serum cystatin C increased less than creatinine
and β2-microglobulin (1.6 versus times), and from stage 3b
serum creatinine also increased less than β2-microglobulin
(2.2 versus 2.5 times). These differences increased with the
worsening of renal function: at CKD stage 5 the increases
of serum cystatin C, creatinine and β2-microglobulin were
4.9, 6.4 and 7.3 times the values in patients at CKD stage 1.
The specificity of the various markers was also affected
differently by GFR impairment (Table 4). A relevant num-
ber of false positive values of plasma NGAL was found
already at CKD stages 2 and 3a, and at CKD stage 5 the
percentage of false positive values was 100%. The false
positive results of urinary NGAL were low at early CKD
stages, but progressively increased up to 40% at CKD stage
5. Plasma BNP presented false positive results in a low
percentage of CKD patients.
The urinary concentration and FE of NGAL were sig-
nificantly increased at CKD stages 4 and 5, respectively
(Figure 4). Urinary concentration of NGAL, but not FE
of NGAL, also significantly increased when plasma NGAL
was higher than 400 ng/ml. Urinary concentrations and
FE of cystatin C and β2-microglobulin increased to a
higher extent than NGAL with the reduction of GFR, and
with the increase in their plasma levels.
Multiple regression analysis demonstrated that urin-
ary NGAL is significantly correlated with plasma NGAL
(P < 0.0001), with urinary β2-microglobulin (P < 0.0001),
and with urinary albumin concentration (P = 0.005). In
patients with urinary protein concentration <200 mg/l
(mean 35 ± 43), urinary NGAL was 13 ± 26 ng/ml; while
in patients with urinary albumin >2 g/l (mean 4.7 ± 4.0),
urinary NGAL was significantly higher (41 ± 71 ng/ml;
P < 0.001)inary neutrophil gelatinase-associated lipocalin and plasma B-type
etermination R2, and statistical significance of the correlations are
L, neutrophil gelatinase-associated lipocalin.
Table 3 Accuracy of blood and urinary concentrations of the different markers as indicators of different degrees of
glomerular filtration rate impairment evaluated by means of receiver operating curves











AUC 0.838***** 0.845***** 0.872***** 0.912***** 0.929*****
Criterion >102 >136 >213 >214 >270
Sensitivity 69.8 77.4 77.0 92.1 100
Specificity 87.5 82.0 84.3 76.1 75.5
Plasma BNP (pg/ml)
AUC 0.613** 0.599** 0.588* 0.623** 0.579 NS
Criterion >31.3 >51.9 >26.6 >26.6 >28.3
Sensitivity 34 25 48 54 50
Specificity 85 93 71 68 67
Serum creatinine (mg/dl)
AUC 0.895***** 0.908***** 0.943***** 0.977***** 0.990*****
Criterion >1.01 >1.25 >1.55 >2.14 >3.08
Sensitivity 82.9 81.0 85.6 90.2 100
Specificity 85.6 81.7 89.2 96.7 94
Urinary NGAL (ng/ml)
AUC 0.555 NS 0.601** 0.617*** 0.635**** 0.773***
Criterion >8.2 >14.4 >20.2 >22.0
Sensitivity 49 42 47.6 70
Specificity 68 80 83 81
Values of the areas under the curve (AUC), criterion values, and sensitivity and specificity values are reported. The statistical significance of the different
AUCs is indicated. *P < 0.05; **P < 0.01; ***P < 0.001;****P < 0.00001. BNP, B-type natriuretic peptide; GFR, glomerular filtration rate; NGAL, neutrophil
gelatinase-associated lipocalin.
Figure 3 Plasma concentrations of the various markers in
comparison with an ideal marker of glomerular filtration rate
impairment. Patients are clustered in groups according to
chronic kidney disease (CKD) stage. Values are scaled on the
mean values of CKD patients at stage 1. GFR, glomerular filtration
rate; NGAL, neutrophil gelatinase-associated lipocalin; P, plasma;
S, serum.
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Plasma NGAL values were significantly higher in kidney
donors (post nephrectomy) than in potential kidney donors
(Table 5). Plasma NGAL levels were also significantly
higher in diabetics and in chronic glomerulonephrites
than in kidney donors, even if the three groups of patients
had similar values of GFR. Plasma BNP was also affected
by the cause of renal disease. In fact, BNP was significantly
higher in renal transplant recipients and in diabetics than
in kidney donors with similar levels of GFR. On the
contrary, urinary NGAL showed only slight differences
according to the cause of kidney disease. Urinary excre-
tion of tubular enzymes NAG and LDH were similar in all
patients, while GGT modestly, but significantly, decreased
with the reduction in GFR.
Maintenance hemodialysis patients
In MHD patients, dialysis with high-flux membranes
decreased plasma NGAL by 35.5% (P < 0.0001), while low-
flux membranes did not remove plasma NGAL. Plasma
BNP was also markedly decreased (−43.1%, P = 0.0005)
after dialysis with high-flux membranes, more than with
low-flux membranes (−13.8%, P =NS) (Figure 5).
Table 4 Percentage of patients with values of the markers above the upper limit of the reference ranges in the
different functional stages of chronic kidney disease







1 48 1/48 2 2/48 4 2/48 4
2 85 18/85 21 1/85 1 2/85 2
3a 64 31/64 48 3/64 5 7/64 11
3b 50 36/50 72 3/50 6 4/50 8
4 43 39/43 91 5/43 12 9/43 21
5 20 20/20 100 8/20 40 3/20 15
Overall 310 145/310 47 22/310 7 27/310 9
BNP, B-type natriuretic peptide; CKD, chronic kidney disease; NGAL, neutrophil gelatinase-associated lipocalin.
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NGAL is a LMWP (molecular weight (MW) 25 kDa) of the
lipocalin family, which is constitutively and/or inducibly
expressed in different tissues and cells [18,19]. NGAL is
cleared from the plasma mainly through glomerular filtra-
tion. After filtration, NGAL is avidly reabsorbed into prox-
imal tubular cells by endocytosis via the megalin system
[20]. AKI upregulates NGAL mRNA in distal renal tubules,
and also increases the production of NGAL by the lung,
liver, and leukocytes [21]. In AKI, NGAL arrives into the
urine from specific cells of distal tubule where it is overex-
pressed during tubular stress [22,23]. Furthermore, when
the proximal tubule is damaged by acute tubular necrosis,Figure 4 Urinary concentration and fractional excretion of neutrophil
excretion of neutrophil gelatinase-associated lipocalin (NGAL) in patients cl
part) or according to plasma concentrations (lower part). Mean values and
differences versus the mean values in patients with GFR >90 ml/minute/1.7
concentrations of plasma NGAL are reported. *P < 0.05.filtered NGAL can escape tubular reabsorption and is
excreted with the urine. Finally, when high plasma NGAL
and the consequent high filtered charge saturates the
tubular reabsorption capacity, the urinary excretion of
NGAL could also increase, similar to other LMWPs [24].
Plasma and urinary concentrations of NGAL have been
indicated as sensitive markers of AKI, in different clinical
settings. A meta-analysis of data from 19 studies indicates
that both plasma/serum and urine NGAL appear to
perform similarly well for diagnostic and prognostic evalu-
ation of AKI [25].
BNP is a LMWP (MW 6.5 kDa) that belongs to the
family of natriuretic peptides. It is produced by enzymaticgelatinase-associated lipocalin. Urinary concentration and fractional
ustered in groups according to glomerular filtration rate (GFR; upper
standard deviations are reported. The statistical significance of the
3 m2 and versus the mean values in patients with the lowest blood
Table 5 Plasma and urinary concentrations of NGAL, BNP and, for comparison, serum and urinary concentrations of various markers of GFR impairment and















Number 33 45 42 50 63 29 36
Age (years) 50.2 ± 1.6 53.0 ± 1.6 41.8 ± 1.7***++++ 43.2 ± 2.2* 55.5 ± 1.7* 58.1 ± 2.8* 49.9 ± 2.7
GFR (ml/minute/1.73 m2) 96.5 ± 3.6 62.4 ± 2.5**** 47.4 ± 2.3****++++ 58.6 ± 4.2**** 38.3 ± 3.3****++++ 43.5 ± 5.7****++ 65.1 ± 6.5**++
Plasma NGAL (ng/ml) 55.9 ± 5.3 112.4 ± 11.3**** 242.6 ± 34.6****+++ 272.9 ± 50.1****++ 456.8 ± 50.87****++++ 371.1 ± 64.9****+++ 215.6 ± 31.0****++
Plasma BNP (pg/ml) 19.1 ± 4.4 20.2 ± 0.9 56 ± 12.3**++ 16.6 ± 3.1 35.9 ± 6.4**++ 79.3 ± 31.6 48.2 ± 8.8**++
Serum creatinine (mg/dl) 0.8 ± 0.03 1.2 ± 0.04**** 1.7 ± 0.1****++++ 1.8 ± 0.2****++ 2.6 ± 0.2****++++ 2.2 ± 0.3***++ 1.6 ± 0.13**+
Serum cystatin C (mg/l) 0.7 ± 0.03 1.1 ± 0.11**** 1.6 ± 0.1****++++ 1.6 ± 0.1****++ 2.1 ± 0.1****++++ 2.1 ± 0.3****+++ 1.5 ± 0.1***+
Serum β2-microglobulin (mg/l) 1.2 ± 0.04 1.9 ± 0.04**** 3.0 ± 0.3****++ 3.1 ± 0.4****++ 4.8 ± 0.4****++++ 4.4 ± 0.7***++ 2.8 ± 0.3***++
Urinary NGAL (ng/ml) 12.4 ± 4.6 10.1 ± 2.7 21.1 ± 7.0 27.3 ± 7.2+ 45.3 ± 9.9**+++ 17.4 ± 5.3 13.8 ± 3.4
Urinary albumin (mg/dl) 6.3 ± 4.3 1.6 ± 0.4 16.4 ± 8.4 184 ± 49***+++ 52.9 ± 8.4****++++ 60.0 ± 18.3**++ 36.2 ± 11.2*
Urinary cystatin C (mg/l) 0.1 ± 0.07 0.1 ± 0.04 0.2 ± 0.09 0.9 ± 0.47 0.6 ± 0.16*++ 0.4 ± 0.14 0.1 ± 0.04
Urinary β2-microglobulin (mg/l) 0.1 ± 0.06 0.3 ± 0.08* 1.7 ± 0.5***++ 3.7 ± 1.6*+ 5.2 ± 1.5***++ 3.1 ± 1.4*+ 1.1 ± 0.3*
Urinary GGT (u/l) 68.7 ± 9.5 29.0 ± 2.7*** 40.6 ± 6.4* 63.6 ± 6.0++++ 38.0 ± 4.5** 47.0 ± 9.1 43.3 ± 6.7**
Urinary LDH (u/l) 29.0 ± 4.1 18.3 ± 2.6* 17.3 ± 2.0* 51.8 ± 12.6+ 25.0 ± 2.4+ 47.3 ± 19.1 31.2 ± 6.5
Urinary NAG (u/l) 5.3 ± 0.6 5.1 ± 0.8 5.6 ± 0.5 6.8 ± 0.6+ 7.1 ± 0.6*++ 7.0 ± 0.9 5.7 ± 0.8
Mean values ± standard errors of the mean are reported. The significance of the differences with mean values of potential kidney donors and of kidney donors is indicated: *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001; +P < 0.05; ++P < 0.01; +++P < 0.001; +++P < 0.0001. BNP, B-type natriuretic peptide; GGT, gamma-glutamyl-transferase; GFR, glomerular filtration rate; LDH, lactate dehydrogenase; NAG, N-acetyl-β-












Figure 5 Plasma concentrations of neutrophil gelatinase-associated lipocalin and B-type natriuretic peptide before and after a dialysis
session with high-flux or low-flux membranes. Plasma concentrations of neutrophil gelatinase-associated lipocalin (NGAL; left side) and B-type
natriuretic peptide (BNP; right side) before and after a dialysis session with high-flux (HF; ○) membrane in 21 patients or with low-flux (LF; ●)
membranes in 23 patients. Mean values ± standard error of the mean are reported.
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http://ccforum.com/content/18/1/R39cleavage of pro-BNP, which is secreted into the plasma
from the myocardial cells in patients with left ventricular
hypertrophy and/or dysfunction, or fluid overload. Plasma
BNP can assess the occurrence, severity and prognosis of
acute and chronic heart failure. BNP is cleared from the
plasma not only by the kidneys, via glomerular filtration
and tubular catabolism, but also due to its cleavage by
proteolytic enzymes.
The concurrent cardio-renal assessment, combining the
measurement of BNP and NGAL, has been proposed as a
powerful predictor of AKI [26].
Similarly to other LMWPs cleared by the plasma via
glomerular filtration, one can expect plasma concentrations
of NGAL and BNP to also increase when GFR decreases.
Indeed, it is known that plasma BNP increases in heart fail-
ure patients with decreased renal function, in CKD patients
and, markedly, in MHD patients [7,8]. Different studies
in CKD patients, renal transplant recipients, and diabetics
suggest that plasma and/or urine NGAL are correlated
with serum creatinine and with predicted GFR, or that
NGAL may predict the worsening of renal function
[27-31]. On the other hand, NGAL was not a reliable
predictor of worsening of diabetic nephropathy [32,33]. In
renal transplant recipients, some concern has been raised
about the usefulness of NGAL as a screening test for renal
function impairment [34]. After heart and lung transplant-
ation, plasma NGAL was also not correlated with cystatin
C and estimated GFR [35]. Finally, only urine NGAL was
found to be correlated with CKD in type 2 diabetics with
nephropathy and in pediatric heart transplant recipients
[36,37]. These literature data indicate the need for a study
involving CKD patients at various functional stages with
stable renal function, to evaluate the relationship of
plasma and urine concentrations of NGAL with measured
GFR.
The present study was performed in CKD patients
affected by different kidney diseases, with stable renal
function, and various degrees of GFR impairment, fromnormality to advanced renal failure, to assess the relation-
ship of NGAL and BNP with measured GFR. To clarify
both glomerular and tubular mechanisms of renal hand-
ling of NGAL, plasma and urinary concentrations of the
LMWPs cystatin C (MW 13.4 kDa) and β2-microglobulin
(MW 11.8 kDa), and urinary excretion of tubular enzymes
were also measured. The reference intervals of the different
index tests, measured in potential kidney donors, agreed
with data from the literature. However, note that the
modest number of subjects and their gender and age
distribution do not allow one to consider the results ob-
tained to be true reference intervals.
The major result of this study is that, in CKD patients
with stable renal function, plasma NGAL concentration
increases progressively with the reduction of GFR, accord-
ing to an exponential function similar to those of serum
markers of GFR impairment. These results demonstrate
that plasma removal of NGAL is greatly impaired by the
decrease of GFR, reducing the accuracy of NGAL as a
marker of AKI. In fact, increased plasma values of NGAL,
suggestive for AKI, were found in a high percentage of
CKD patients with stably impaired renal function. The
percentage of false positive NGAL increased with the
stage of CKD, up to 100% at CKD stage 5. Other literature
data indicate that plasma NGAL levels do not adequately
predict AKI in patients with acute heart failure, and were
significantly correlated with serum creatinine values at
presentation [38]. According to a recent study, the choice
of a higher threshold (plasma NGAL >400 ng/ml) increases
the specificity for the diagnosis of AKI among emergency
department patients, with a pre-existing CKD [39].
Furthermore, in the present study, the increase in plasma
NGAL concentration found with decreasing GFR was too
high to consider NGAL an ideal marker of GFR, suggesting
that NGAL production increases in renal failure. Hypothet-
ically, similar results could also be due the interference of
increased plasma values of homodimer NGAL, which due
to its MW of ~50 kDa has a low filtration coefficient [40].
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plasma BNP increase significantly with the reduction of
GFR. However, urinary NGAL is less affected than plasma
NGAL by the level of GFR and its reabsorption by the
proximal tubule is not easily saturated. In fact, urinary
NGAL increased only at CKD stage 4 and when the plasma
concentration of NGAL was quite high (>400 ng/ml), while
its FE remained quite low, lower than those of the two
other LMWPs cystatin C and β2-microglobulin. The effect
of the reduction of GFR was even lower on plasma BNP,
which, possibly due to its extra-renal clearance, increased
markedly only in MHD patients, as reported previously
[7,8]. The relationships between urinary NGAL and urin-
ary albumin and β2-microglobulin suggest a possible com-
petition for tubular reabsorption of NGAL with albumin
and β2-microglobulin. These data are in agreement with
animal data demonstrating that proteinuria was associated
with increasing urinary NGAL concentrations [41]. Fur-
ther studies are needed to establish the necessity of dif-
ferent reference ranges for urinary NGAL in patients
with proteinuria.
A clear difference is evident in the relationship with
GFR between urinary excretion of functional and injury
markers. In fact, urinary excretions of functional markers
(cystatin C and β2-microglobulin) increase with the reduc-
tion of GFR, due to the saturation of their tubular reabsorp-
tion. To the contrary, injury markers (LDH and NAG)
are not affected by the decrease of GFR, or eventually the
urinary excretion (GGT) may decrease with the reduction
of GFR, probably due to the reduction of renal mass. The
behavior of NGAL appears similar to that of functional
markers.
The increase in plasma concentration and urinary
excretion of NGAL that accompanies the decrease of
GFR may be determined by an increase of its extra-renal
production, justified by the proinflammatory status of
CKD and/or by its increased production by inflamed
tubular cells in CKD patients, as suggested by the forest
fire theory proposed by Mori and Nakao [42]. The differ-
ent effect of the various underlying kidney diseases on
plasma and urine NGAL concentrations is in agreement
with this theory. On the other hand, the doubling of
plasma NGAL in healthy living kidney donors, which is
not accompanied by an increase in urinary NGAL or in
tubular enzymes, indicates a significant effect of the
reduction of GFR per se. Finally, the relevance of the
level of GFR on plasma NGAL concentration is clearly
indicated by the extremely high plasma NGAL measured
in MHD patients with no residual renal function. In MHD
only hemodialysis with high-flux membranes removes
plasma NGAL, due to its quite high MW. Thus, it is im-
portant to consider that the treatment of severe AKI by
hemodialysis can mask a persistent increase in plasma
NGAL. In MHD patients, plasma BNP concentrations arelowered by both low-flux and high-flux hemodialysis, in
agreement with literature data [7,8,43-45]. The possible
removal of BNP by dialysis must therefore be considered
when evaluating the effect of HD treatment on heart
failure.
Conclusions
Plasma NGAL increases markedly with a reduction in
GFR in stable CKD patients, potentially producing a very
high number of false positive diagnoses for AKI. GFR
impairment and the etiology of kidney disease have a
more relevant effect on plasma NGAL than on urinary
NGAL. Thus, urine NGAL should be more accurate than
plasma NGAL as a marker of AKI in CKD patients. In any
case, specific reference values of NGAL and BNP should
be used in CKD patients, according to the CKD stage.
Key messages
 The impairment of GFR in CKD patients affects
mainly plasma NGAL, and to a lower extent urinary
NGAL and plasma BNP.
 The increased values of plasma NGAL could
determine a high number of false positive diagnoses
for AKI in stable CKD patients.
 Specific reference ranges for NGAL and BNP should
be used in CKD patients, according to the CKD
stage.
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